Phase I/II clinical study of JVC-001

An open-label, randomized, clinical study assessing the safety and immunogenicity of JVC-001 in Japanese healthy children

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222978

Enrollment

100

Registered

2015-10-05

Start date

2015-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of measles, mumps and rubella

Interventions

investigational material(s) Generic name etc : JVC-001 INN of investigational material : - Therapeutic category code : 631 Vaccines Dosage and Administration for Investigational material : subcutaneou

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aged 12 months and older and younger than 24 months

Exclusion criteria

Exclusion criteria: 1) Subjects with history of measles, mumps, or rubella infection 2) Subjects with history of measles, mumps, or rubella virus vaccination

Design outcomes

Primary

Measure	Time frame
safety efficacy 1) immunogenicity against measles virus, rubella virus and mumps virus (Genotype D) 2) Adverse events, solicited adverse events/symptoms (local, general)	—

Secondary

Measure	Time frame
efficacy immunogenicity against several genotypes of mumps viruses	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026